June 1, 2023
(OrthoSpineNews)- Kolosis BIO (Kolosis), a leading provider of biologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are excited to announce their partnership in the surgical incision market. This strategic collaboration represents Kolosis BIO’s expansion into a new area of healthcare, while providing MTF with a focused partner to fully leverage the potential of their exceptional tissues in this market. Together, the two companies are dedicated to advancing surgical technologies and driving improvements in patient outcomes.
“We are thrilled to embark on this strategic partnership with MTF Biologics, a global leader in tissue processing,” said Collin Begley, CEO of Kolosis BIO. “Our longstanding relationship with MTF has been built on a foundation of trust, collaboration, and a shared commitment to innovation. Together, we are dedicated to bringing outstanding technologies to patients, and this expansion into surgical incision represents an exciting milestone for us. By leveraging our strong market channel and extending our reach beyond bone graft solutions, we are poised to deliver additional transformative product offerings to the operating room.”
Kim Rounds, Vice President & General Manager, Wound Care Franchise at MTF Biologics, expressed enthusiasm for the collaboration, stating, “This partnership with Kolosis allows MTF to add a strategic partner who can further leverage our best-in-class placental tissues to optimize surgical outcomes. The anti-microbial, anti-adhesive, and anti-inflammatory properties of human amniotic tissue can be beneficial in the presence of patient and /or incision healing risk factors. We are excited to work together to advance surgical incision care, specifically benefiting patients in the spine and orthopedic fields.”
This strategic partnership between Kolosis BIO and MTF Biologics marks a significant milestone in their shared mission to provide advanced solutions to healthcare providers and drive positive patient outcomes. The companies are excited about the opportunity to develop innovative technologies and establish new standards in surgical incision management, driving advancements in patient care.
As the company looks to the future, Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit www.kolosis.com.